Glymphatic dysfunction in neurodegeneration: From impaired clearance to mechanism-driven therapeutic innovation

Current Opinion in Pharmacology · Published 2026-06-19 · DOI 10.1016/j.coph.2026.102647

Authors (2)

Palak Kalra, Amarjot Kaur Grewal

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Kalra, P., Grewal, A. (2026). Glymphatic dysfunction in neurodegeneration: From impaired clearance to mechanism-driven therapeutic innovation. Current Opinion in Pharmacology. https://doi.org/10.1016/j.coph.2026.102647

Related articles

• Immune cell subtype contributions to doxorubicin cardiotoxicity–defining immune targets for translational interventions · Current Opinion in Pharmacology · 2025 · Same journal
• Lipidomics-driven insights into acupuncture mechanisms: From dynamic signaling networks to multi-dimensional regulations · Current Opinion in Pharmacology · 2025 · Same journal
• Revolutionizing Crohn's disease monitoring: The emerging role of intestinal ultrasound · Current Opinion in Pharmacology · 2025 · Same journal
• The role of plant-derived compounds in anti-obesity drug discovery: A molecular perspective · Current Opinion in Pharmacology · 2025 · Same journal
• Electro-microbial interplay in the gut–brain axis: An emerging paradigm for gut microbiota modulation via vagus nerve stimulation · Current Opinion in Pharmacology · 2025 · Same journal
• Ivermectin and non-parasitic disorders: An update · Current Opinion in Pharmacology · 2025 · Same journal
• Pharmacological silence: Revisiting the clinical and molecular impact of inactive metabolites · Current Opinion in Pharmacology · 2026 · Same journal
• Nutritional composition of diets for inducing and maintaining remission in inflammatory bowel diseases: from bedside to plate · Current Opinion in Pharmacology · 2025 · Same journal
• The neuro-metabolic epidemic and the CB1R paradox · Current Opinion in Pharmacology · 2026 · Same journal
• Real-world evidence supporting orphan drugs approvals for rare neuromuscular disorders in the European Union and the United States: Review of public assessment reports (2015–2025) · Current Opinion in Pharmacology · 2025 · Same journal